A citation-based method for searching scientific literature

M Nauck, F Stöckmann, R Ebert, W Creutzfeldt. Diabetologia 1986
Times Cited: 913







List of co-cited articles
1110 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses.
M A Nauck, E Homberger, E G Siegel, R C Allen, R P Eaton, R Ebert, W Creutzfeldt. J Clin Endocrinol Metab 1986
597
27

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Steven P Marso, Stephen C Bain, Agostino Consoli, Freddy G Eliaschewitz, Esteban Jódar, Lawrence A Leiter, Ildiko Lingvay, Julio Rosenstock, Jochen Seufert, Mark L Warren,[...]. N Engl J Med 2016
25

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
Steven P Marso, Gilbert H Daniels, Kirstine Brown-Frandsen, Peter Kristensen, Johannes F E Mann, Michael A Nauck, Steven E Nissen, Stuart Pocock, Neil R Poulter, Lasse S Ravn,[...]. N Engl J Med 2016
24


Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.
Hertzel C Gerstein, Helen M Colhoun, Gilles R Dagenais, Rafael Diaz, Mark Lakshmanan, Prem Pais, Jeffrey Probstfield, Jeffrey S Riesmeyer, Matthew C Riddle, Lars Rydén,[...]. Lancet 2019
978
22

Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
Juan Pablo Frias, Michael A Nauck, Joanna Van, Mark E Kutner, Xuewei Cui, Charles Benson, Shweta Urva, Ruth E Gimeno, Zvonko Milicevic, Deborah Robins,[...]. Lancet 2018
344
21

Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome.
Marc A Pfeffer, Brian Claggett, Rafael Diaz, Kenneth Dickstein, Hertzel C Gerstein, Lars V Køber, Francesca C Lawson, Lin Ping, Xiaodan Wei, Eldrin F Lewis,[...]. N Engl J Med 2015
19

Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.
Rury R Holman, M Angelyn Bethel, Robert J Mentz, Vivian P Thompson, Yuliya Lokhnygina, John B Buse, Juliana C Chan, Jasmine Choi, Stephanie M Gustavson, Nayyar Iqbal,[...]. N Engl J Med 2017
18


Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial.
Adrian F Hernandez, Jennifer B Green, Salim Janmohamed, Ralph B D'Agostino, Christopher B Granger, Nigel P Jones, Lawrence A Leiter, Anne E Rosenberg, Kristina N Sigmon, Matthew C Somerville,[...]. Lancet 2018
806
17

The physiology of glucagon-like peptide 1.
Jens Juul Holst. Physiol Rev 2007
17



Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Mansoor Husain, Andreas L Birkenfeld, Morten Donsmark, Kathleen Dungan, Freddy G Eliaschewitz, Denise R Franco, Ole K Jeppesen, Ildiko Lingvay, Ofri Mosenzon, Sue D Pedersen,[...]. N Engl J Med 2019
599
16


Reduced incretin effect in type 2 diabetes: cause or consequence of the diabetic state?
Filip K Knop, Tina Vilsbøll, Patricia V Højberg, Steen Larsen, Sten Madsbad, Aage Vølund, Jens J Holst, Thure Krarup. Diabetes 2007
230
16

Separate and Combined Glucometabolic Effects of Endogenous Glucose-Dependent Insulinotropic Polypeptide and Glucagon-like Peptide 1 in Healthy Individuals.
Lærke S Gasbjerg, Mads M Helsted, Bolette Hartmann, Mette H Jensen, Maria B N Gabe, Alexander H Sparre-Ulrich, Simon Veedfald, Signe Stensen, Amalie R Lanng, Natasha C Bergmann,[...]. Diabetes 2019
75
20

Biology of incretins: GLP-1 and GIP.
Laurie L Baggio, Daniel J Drucker. Gastroenterology 2007
14

Pharmacology, physiology, and mechanisms of incretin hormone action.
Jonathan E Campbell, Daniel J Drucker. Cell Metab 2013
842
13

Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients.
M B Toft-Nielsen, M B Damholt, S Madsbad, L M Hilsted, T E Hughes, B K Michelsen, J J Holst. J Clin Endocrinol Metab 2001
643
12

Stimulation of insulin secretion by gastric inhibitory polypeptide in man.
J Dupre, S A Ross, D Watson, J C Brown. J Clin Endocrinol Metab 1973
734
12

Impaired regulation of the incretin effect in patients with type 2 diabetes.
Jonatan I Bagger, Filip K Knop, Asger Lund, Henrik Vestergaard, Jens J Holst, Tina Vilsbøll. J Clin Endocrinol Metab 2011
148
12


Glucagon-like peptide-1 7-36: a physiological incretin in man.
B Kreymann, G Williams, M A Ghatei, S R Bloom. Lancet 1987
11

Inhibition of gastric inhibitory polypeptide signaling prevents obesity.
Kazumasa Miyawaki, Yuichiro Yamada, Nobuhiro Ban, Yu Ihara, Katsushi Tsukiyama, Heying Zhou, Shimpei Fujimoto, Akira Oku, Kinsuke Tsuda, Shinya Toyokuni,[...]. Nat Med 2002
641
11

LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept.
Tamer Coskun, Kyle W Sloop, Corina Loghin, Jorge Alsina-Fernandez, Shweta Urva, Krister B Bokvist, Xuewei Cui, Daniel A Briere, Over Cabrera, William C Roell,[...]. Mol Metab 2018
207
11


Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes.
Jennifer B Green, M Angelyn Bethel, Paul W Armstrong, John B Buse, Samuel S Engel, Jyotsna Garg, Robert Josse, Keith D Kaufman, Joerg Koglin, Scott Korn,[...]. N Engl J Med 2015
11

Incretin hormones: Their role in health and disease.
Michael A Nauck, Juris J Meier. Diabetes Obes Metab 2018
262
11

The incretin concept today.
W Creutzfeldt. Diabetologia 1979
660
10

Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gut.
J J Holst, C Orskov, O V Nielsen, T W Schwartz. FEBS Lett 1987
495
10


Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.
Benjamin M Scirica, Deepak L Bhatt, Eugene Braunwald, P Gabriel Steg, Jaime Davidson, Boaz Hirshberg, Peter Ohman, Robert Frederich, Stephen D Wiviott, Elaine B Hoffman,[...]. N Engl J Med 2013
10


Glucagon-like peptide 1 (GLP-1).
T D Müller, B Finan, S R Bloom, D D'Alessio, D J Drucker, P R Flatt, A Fritsche, F Gribble, H J Grill, J F Habener,[...]. Mol Metab 2019
439
10

Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia.
J J Meier, B Gallwitz, N Siepmann, J J Holst, C F Deacon, W E Schmidt, M A Nauck. Diabetologia 2003
224
9


Secretion of glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes: systematic review and meta-analysis of clinical studies.
Salvatore Calanna, Mikkel Christensen, Jens J Holst, Blandine Laferrère, Lise L Gluud, Tina Vilsbøll, Filip K Knop. Diabetes Care 2013
99
9

Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism.
Piotr A Mroz, Brian Finan, Vasily Gelfanov, Bin Yang, Matthias H Tschöp, Richard D DiMarchi, Diego Perez-Tilve. Mol Metab 2019
85
10

Glucose-dependent insulinotropic polypeptide: a bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans.
Mikkel Christensen, Louise Vedtofte, Jens J Holst, Tina Vilsbøll, Filip K Knop. Diabetes 2011
210
9

Impaired incretin effect and fasting hyperglucagonaemia characterizing type 2 diabetic subjects are early signs of dysmetabolism in obesity.
Filip K Knop, K Aaboe, T Vilsbøll, A Vølund, J J Holst, T Krarup, S Madsbad. Diabetes Obes Metab 2012
123
9

Insulin Secretion Depends on Intra-islet Glucagon Signaling.
Berit Svendsen, Olav Larsen, Maria Buur Nordskov Gabe, Charlotte Bayer Christiansen, Mette M Rosenkilde, Daniel J Drucker, Jens Juul Holst. Cell Rep 2018
155
9

Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial.
Julio Rosenstock, Vlado Perkovic, Odd Erik Johansen, Mark E Cooper, Steven E Kahn, Nikolaus Marx, John H Alexander, Michael Pencina, Robert D Toto, Christoph Wanner,[...]. JAMA 2019
551
9

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
9

Alogliptin after acute coronary syndrome in patients with type 2 diabetes.
William B White, Christopher P Cannon, Simon R Heller, Steven E Nissen, Richard M Bergenstal, George L Bakris, Alfonso T Perez, Penny R Fleck, Cyrus R Mehta, Stuart Kupfer,[...]. N Engl J Med 2013
9

Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?
M A Nauck, I Vardarli, C F Deacon, J J Holst, J J Meier. Diabetologia 2011
315
9


Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
Juan P Frías, Melanie J Davies, Julio Rosenstock, Federico C Pérez Manghi, Laura Fernández Landó, Brandon K Bergman, Bing Liu, Xuewei Cui, Katelyn Brown. N Engl J Med 2021
166
9

Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.
Julio Rosenstock, Carol Wysham, Juan P Frías, Shizuka Kaneko, Clare J Lee, Laura Fernández Landó, Huzhang Mao, Xuewei Cui, Chrisanthi A Karanikas, Vivian T Thieu. Lancet 2021
110
9

PLASMA INSULIN RESPONSE TO ORAL AND INTRAVENOUS GLUCOSE ADMINISTRATION.
H ELRICK, L STIMMLER, C J HLAD, Y ARAI. J Clin Endocrinol Metab 1964
681
8


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.